Treatment of seasonal and perennial rhinitis with intranasal flunisolide.
Flunisolide (F), a potent fluorinated corticosteroid or its propylene/polyethylene glycol vehicle (V) were intranasally administered to 50 patients with ragweed hayfever and 75 patients with perennial rhinitis. Each patient was randomly assigned in a double-blind manner an indistinguishable metered pump spray device containing either F or V. Each hayfever patient administered two puffs in each nostril b.i.d. Each perennial rhinitis patient administered two puffs in each nostril t.i.d. Each puff of F contained 25 micrograms F. Hayfever and perennial rhinitis patients inhaling F demonstrated significantly lowered symptom scores compared to their V controls. Skin test positive patients with perennial rhinitis inhaling F demonstrated significantly large reductions in symptom scores and significantly greater subjective control of symptoms compared to their V control than their skin test negative counterparts inhaling F and V. Morning plasma cortisol measured prior to and at the end of 1 month and 3 months of F revealed no significant diminution in cortisol level compared to patients inhaling V. No long-term adverse local or systemic steroid effects attributable to F were observed. Flunisolide spray is a safe and effective modality for the treatment of seasonal and perennial rhinitis.
D000281:Administration, Intranasal; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008134:Long-Term Care; D010919:Placebos; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000188:drug therapy*; D012882:Skin Tests; D013997:Time Factors
D010919:Placebos; D005446:Fluocinolone Acetonide; C007734:flunisolide; D006854:Hydrocortisone